Prometheus Biosciences And Dr. Falk Pharma Advance PR600 And Trigger Final Preclinical Milestone Payment

Published by
The Street

By GlobeNewswire SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) — Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced it has received its final preclinical milestone payment from Dr. Falk Pharma GmbH under its collaboration agreement to develop and commercialize Prometheus’ second program, PR600. The milestone was based on Prometheus’ development of a propr…

Read more

Panaxia’s Facility In Malta Granted EU-GMP Standard

Published by
The Street

By PR Newswire TEL AVIV, Israel, Jan. 3, 2022 /PRNewswire/ — Panaxia Global, the controlling owner of Panaxia Labs Israel Ltd. (TASE: PNAX), a global pharma company that develops, manufactures and markets progressive cannabis-based products in pharmaceutical quality, announced today that it has received official approval for the EU-GMP standard for its production facility in Malta from EU Health Authority. This standard is binding and essential for the production, export and marketing of medical cannabis products in EU countries, in accordance with the standards accepted under the European Di…

Read more